Report on recent discontinuation of tyrosine kinase inhibitors and alternative approaches to eradicating the chronic myeloid leukemia stem cells in the 55th ASH annual meeting
10.3760/cma.j.issn.1009-9921.2014.01.006
- VernacularTitle:酪氨酸激酶抑制剂治疗中停药问题及根除慢性髓系白血病干细胞的治疗选择:第55届美国血液学会年会报道
- Author:
Yingyu CHEN
;
Jianda HU
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,chronic;
Tyrosine kinase inhibitor;
Discontinuation;
Stem cells;
ASH annual meeting
- From:
Journal of Leukemia & Lymphoma
2014;23(1):12-16
- CountryChina
- Language:Chinese
-
Abstract:
Tyrosine kinase inhibitor (TKI) may significantly improve the treatment outcome in chronic myeloid leukemia (CML).It is the most frequent question about whether the patients with durable complete molecular response (CMR) can safely discontinue TKI treatment without relapse.This has focused attention on the strategies to eradicate residual CML cells,especially the CML stem cells,which should result in long term leukemia-free survival and permanent cure.Here,the progress on discontinuation of TKI therapy and alternative approaches to eradicating CML stem cells in the 55th ASH annual meeting is reviewed.
